Albireo Pharma, Inc. (NASDAQ: ALBO at https://www.webull.com/quote/nasdaq-albo) is a well-known biopharmaceutical company that mainly works on the development and commercialization of different novel bile acid modulators. These help in treating different orphan pediatric liver diseases and critical GI disorders in the USA. Albireo Pharma is also developing Elobixibat which is an IBAT inhibitor. Currently, it is in phase 111 and the company is conducting clinical trials to confirm if it is getting success to treat biliary atresia.
NASDAQ: ALBO latest stock market updates
Albireo Pharma (NASDAQ: ALBO) stock was trading at $17.63 on March 11th, 2020 when the COVID-19 pandemic hit the world. Since then, ALBO stock value increased by 52.2%. Today it is trading now at $26.83 (as of 13th August 2020). This organization earned $20.60 million during the quarter; compared to the consensus estimate of $19.10 million. ALBO had a negative net margin of 722.91% and a negative return on equity of 82.06%. The next earning date is scheduled to release on Wednesday, November 4th, 2020. 7 brokers expected Albireo Pharma’s stock price to reach $51.67 in the next twelve months suggesting a possible upside of 111.1% from the stock current price.
Is NASDAQ: ALBO a good stock to buy?
Investors might choose to buy the stock of NASDAQ: ALBO because the security in the medical-Biomedical and Genetics space is seeing solid earnings estimate revision activity in the NASDAQ Industry Rank. The rank of 56 out of more than 250 industries suggesting it is positioned at the top level compared to the other segments. This firm has had solid earnings estimate revision activity over the past months. Now, it is doing great in both the short and long term.
In fact, over the past month, current quarter estimates have narrowed from a loss of $1.39 per share to a loss of $1.36 per share, while current year estimates have narrowed from a loss of $7.13 per share to a loss of $6.96 per share. The company currently carries a Zacks Rank 3 which is also a favorable signal. Not only is this industry on the top list holding the third rank, but it is seeing solid estimate revision as of late, suggesting it could be a very interesting choice for investors seeking.
According to 7 Wall Street analysts, ALBO stocks can be profitable in the future. Last year, they issued “buy”, “hold” and “sell” ratings for NASDAQ: ALBO stocks. They are currently buying ratings for the stock is 7 resulting in the strong recommendation of “buy”.
And there is an increase in total shares from the June 30th (77.8 % increase), so based on an average trading volume of 80,000 shares, the days-to-cover ratio is currently 52 days. You can do stock trading from day trading options.
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.